Ontozry

News

Angelini rapped for criticism of EMA approval

Angelini has been rapped under the UK pharma industry's code of practice for criticising licensing decisions made by the EMA and other breaches.

News

Illustration of a nerve cell on a colored background with light effects

Drug-resistant epilepsy drug Ontozry backed by NICE

NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini group company Arvelle Pharm

News

Moderna Innovation and Technology Centre

Moderna jab on trial for cancer-causing syndrome

Patients with Lynch syndrome could have a potential treatment on the horizon, as a Moderna mRNA vaccine starts trials at Oxford University.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks